Clinical characteristics and outcomes of patients with Burkholderia cepacia bacteremia in an intensive care unit

Diagnostic Microbiology and Infectious Disease

Volumn 70, Issue 2, 2011, Pages 260-266

  Liao, Chun Hsing ^a   Chang, Hou Tai ^a   Lai, Chih Cheng ^b   Huang, Yu Tsung ^c   Hsu, Meng Shuian ^a   Liu, Chia Ying ^a   Yang, Chia Jui ^a   Hsueh, Po Ren ^c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antimicrobial susceptibility; Bacteremia; Burkholderia cepacia; Outbreak; Treatment outcomes

Indexed keywords

CEFTAZIDIME; COLISTIN; COTRIMOXAZOLE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; TIGECYCLINE;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BURKHOLDERIA CEPACIA; BURKHOLDERIA INFECTION; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTRACHEAL INTUBATION; EPIDEMIC; FEMALE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PULSED FIELD GEL ELECTROPHORESIS; SCORING SYSTEM; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL RATE; TAIWAN;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL TYPING TECHNIQUES; BURKHOLDERIA CEPACIA; BURKHOLDERIA INFECTIONS; COHORT STUDIES; DISEASE OUTBREAKS; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; GENOTYPE; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR TYPING; RISK FACTORS; TAIWAN; TREATMENT OUTCOME;

EID: 79955979414     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.01.008     Document Type: Article

References (29)

1. Abe K., D'Angelo M.T., Sunenshine R., Noble-Wang J., Cope J., Jensen B., Srinivasan A. Outbreak of Burkholderia cepacia bloodstream infection at an outpatient hematology and oncology practice. Infect. Control Hosp. Epidemiol. 2007, 28:1311-1313.
2. Avgeri S.G., Matthaiou D.K., Dimopoulos G., Grammatikos A.P., Falagas M.E. Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. Int. J. Antimicrob. Agents 2009, 33:394-404.
3. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., Schein R.M., Sibbald W.J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655.
4. Bressler A.M., Kaye K.S., LiPuma J.J., Alexander B.D., Moore C.M., Reller L.B., Woods C.W. Risk factors for Burkholderia cepacia complex bacteremia among intensive care unit patients without cystic fibrosis: a case-control study. Infect. Control Hosp. Epidemiol. 2007, 28:951-958.
5. Chang S.C., Fang C.T., Chen Y.C., Hsueh P.R., Luh K.T., Hsieh W.C. In vitro activity of meropenem against common pathogenic bacteria isolated in Taiwan. Diagn. Microbiol. Infect. Dis. 1998, 32:273-279.
6. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; 20th information supplement, M100-S20 2010, CLSI, Wayne, PA.
7. Fitzsimons S. Cystic Fibrosis Foundation, Cystic Fibrosis Patient Registry report. Pediatr. Pulmonol. 1996, 21:267-275.
8. Gilligan P. Pseudomonas and Burkholderia. Manual of Clinical Microbiology 1991, 509-519. American Society for Microbiology, Washington, DC. 6th ed. P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover, R.H. Yolken (Eds.).
9. Goldmann D.A., Klinger J.D. Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology. J. Pediatr. 1986, 108:806-812.
10. Goven J.R., Hughes J.E., Vandamme P. Burkholderia cepacia: medical, taxonomic and ecological issues. J. Med. Microbiol. 1996, 45:395-407.
11. Gregory W.J., McNabb P.C. Pseudomonas cepacia. Infect. Control 1986, 7:281-284.
12. Hamill R.J., Houston E.D., Georghiou P.R., Wright C.E., Koza M.A., Cadle R.M., Goepfert P.A., Lewis D.A., Zenon G.J., Clarridge J.E. An outbreak of Burkholderia cepacia respiratory colonization and infection associated with nebulized albuterol therapy. Ann. Intern. Med. 1995, 122:762-766.
13. Holmes A., Nolan R., Taylor R., Finley R., Riley M., Jiang R.Z., Steinbach S., Goldstein R. An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis. J. Infect. Dis. 1999, 179:1197-1205.
14. Isles A., Maclusky I., Corey M., Gold R., Prober C., Fleming P., Levison H. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J. Pediatr. 1984, 104:206-210.
15. Jarvis W.R., Olson D., Tablan O., Martone W.J. The epidemiology of nosocomial Pseudomonas cepacia infections. Eur. J. Epidemiol. 1987, 3:233-236.
16. Jones A.M., Dodd M.E., Webb A.K. Burkholderia cepacia: current clinical issues, environmental controversies and ethical dilemmas. Eur. Respir. J. 2001, 17:295-301.
17. Lu D.C., Chang S.C., Chen Y.C., Luh K.T., Lee C.Y., Hsieh W.C. Burkholderia cepacia bacteremia: a retrospective analysis of 70 episodes. J. Formos. Med. Assoc. 1997, 96:972-978.
18. Lu D.C.T., Chang S.C., Chen Y.C., Luh K.T., Hsieh W.C. In vitro activities of antimicrobial agents, alone and in combinations, against Burkholderia cepacia isolated from blood. Diagn. Microbiol. Infect. Dis. 1997, 28:187-191.
19. Mann T., Ben-David D., Zlotkin A., Shachar D., Keller N., Toren A., Nagler A., Smollan G., Barzilai A., Rahav G. An outbreak of Burkholderia cenocepacia bacteremia in immunocompromised oncology patients. Infection 2010, 38:187-194.
20. National Committee for Clinical Laboratory Standards (NCCLS) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 5th edition. (M7-A6) 2004, NCCLS, Wayne, PA.
21. Ouchi K., Abe M., Karita M., Oguri T., Igari J., Nakazawa T. Analysis of strains of Burkholderia (Pseudomonas) cepacia isolated in a nosocomial outbreak by biochemical and genomic typing. J. Clin. Microbiol. 1995, 33:2353-2357.
22. Reboli A.C., Koshinski D.O., Arias K., Marks-Austin K., Stieritz D., Stull T.L. An outbreak of Burkholderia cepacia lower respiratory tract infection associated with contaminated albuterol nebulization solution. Infect. Control Hosp. Epidemiol. 1996, 17:741-743.
23. Segonds C., Heulin T., Marty N., Chabanon G. Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates. J. Clin. Microbiol. 1999, 37:2201-2208.
24. Spencer R.C. The emergence of epidemic multiple antibiotic resistant Stenotrophomonas maltophilia and Burkholderia cepacia. J. Hosp. Infect. 1995, 30(suppl):453-464.
25. Teng L.J., Hsueh P.R., Pan H.I., Ho S.W., Luh K.T. Persistent bacteraemia caused by a single clone of Burkholderia cepacia with unusual phenotype. J. Infect. 2001, 42:202-205.
26. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis criteria for bacterial strain typing. J. Clin. Microbiol. 1995, 33:2233-2239.
27. Vincent J.L., de Mendonça A., Cantraine F., Moreno R., Takala J., Suter P.M., Sprung C.L., Colardyn F., Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit. Care. Med. 1998, 26:1793-1800.
28. Woods C.W., Bressler A.M., LiPuma J.J., Alexander B.D., Clements D.A., Weber D.J., Moore C.M., Reller L.B., Kaye K.S. Virulence associated with outbreak-related strains of Burkholderia cepacia complex among a cohort of patients with bacteremia. Clin. Infect. Dis. 2004, 38:1243-1250.
29. Yu W.L., Wang D.Y., Lin C.W., Tsou M.F. Endemic Burkholderia cepacia bacteremia: clinical susceptibilities of isolates. Scand. J. Infect. Dis. 1999, 31:293-298.